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ABSTRACT
PURPOSE: To evaluate the antitumor and antimicrobial activity of ethanolic extract of Morinda citrifolia L. fruit cultivated in 
southeastern Brazil.
METHODS: Preparation ethanolic extract of the fruit of Morinda citrifolia L. Culture of melanoma cells B16-F10 for treatment with 
ethanolic extract of Morinda citrifolia L. fruit to determine cell viability by MTT and determination temporal effect of ethanolic extract 
fruit on the cell growth B16-F10 for 8 days. Evaluation of antimicrobial activity of ethanolic extract fruit against Staphylococcus aureus 
and Escherichia coli by determination of Minimum Inhibitory Concentration (MIC).
RESULTS: The ethanolic extract of Morinda citrifolia L. fruit (10mg/mL) decreased cellular activity and inhibited 45% the rate of 
cell proliferation of B16-F10 melanoma treated during period studied. The ethanolic extract of Morinda citrifolia L. fruit demonstrated 
antimicrobial activity inhibiting the growth of both microorganisms studied. Staphylococcus aureus was less resistant to ethanolic 
extract of Morinda citrifolia L. fruit than Escherichia coli, 1 mg/mL and 10 mg/mL, respectively.
CONCLUSION: What these results indicate that the ethanolic extract of the fruit of Morinda citrifolia L. showed antitumor activity 
with inhibition of viability and growth of B16-F10 cells and also showed antibacterial activity as induced inhibition of growth of 
Staphylococcus aureus and Escherichia coli.
Key words: Morinda citrifolia L.; Morinda; Drug Screening Assays Antitumor; Anti-Infective Agents; Antimicrobial.
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Introduction
Cutaneous melanoma is considered the most serious type of 
skin cancer. It is a highly lethal and very invasive neoplasm, accounting 
for less than 5 % of all skin cancer cases. Despite its low incidence, it 
is considered a problem for public health due to the significant raise 
in the number of cases, exceeding other malignancies growth rate1-3.
In the last few years there has been growing interest 
in natural products with biological activity, with relevance to 
anticancer activity. A large diversity of plants has been extensively 
investigated, these plants being secondary metabolite producers. 
These studies on the biotechnological potential of plants sources 
promising therapeutic agents are mentioned, with antibacterial, 
antiviral, antitumor and immunossupressive potential3,4.
Morinda citrifolia L, known as Noni, belongs to the 
Rubiaceae family native to Southeast Asia and secularly used 
in Polynesian traditional medicine. Noni juice is widely used in 
complementary medicine due to its probable antioxidant, anti-
inflammatory and antitumor effects against diseases such as 
cancer, atherosclerosis, diabetes and ulcer5,6. 
Products derived from Morinda citrifolia L. fruit have 
been commercialized in the USA since the 1990s and are distributed 
all over the world. A large number of beneficial effects have been 
claimed for Noni. However, clinical data are essentially lacking. 
To what e ffxtent the findings from experimental pharmacological 
studies are of potential clinical relevance is not clear at present7.
Many pharmacological studies of Morinda citrifolia L 
juice and isolated compounds from the fruit has been published. 
These compounds including iridoids, flavonoids, lignans, coumarins 
and anthraquinones7,8. The purposes of this study were to evaluate 
antioxidant, antitumoral and antimicrobial activity of ethanolic 
extract from Morinda citrifolia L. fruit grown in Southeast Brazil.
Methods
Plant materials and preparation of ethanolic extract
The fruits of Morinda citrifolia L. were collect in 
the campus of the State University of Santa Cruz, Bahia, 
Brazil. Voucher specimens were deposited in the Herbarium of 
Department of Biological Sciences, State University of Santa 
Cruz, Bahia, Brazil. The samples were washed with running tap 
water and separated before being chopped into pieces. They were 
oven-dried at 42 °C for 5 days and ground to powder.  
Plant materials used in this study were fresh fruits 
(seedless without core) of Morinda citrifolia L.. The preparation 
of 70% ethanolic extract of dried fruit (50 g) was obtained by 
grinding and exposure to organic solvent. A suspension of dried 
fruit (50 g) in water (150 mL) was extracted with ethanol (350 mL) 
for 8 days. The aqueous layer was evaporated and then followed 
by lyophilization to give a water-soluble fraction.
Cell Culture
The mouse melanoma B16-F10 cell line was purchased from 
Rio de Janeiro Cell Bank (BCRJ/UFRJ). The cells were maintained at 
37 °C in an incubator with a humidified atmosphere of 5 % CO2 and 
cultured in DMEM/F12 supplemented with 10 % heat-inactivated 
FBS, streptomycin (100 μg/mL) and penicillin (100 units/mL).
Effect of ethanolic extract of Morinda citrifolia L on 
B16-F10 cell growth inhibition
B16-F10 cells at 80% confluence, the cells were harvested 
with trypsin, and serum-free medium was used to obtained a single-
cell suspension. The cells were then seeded in 06-well plates at a 
density of 200,000 cells/well. After 24 h, the wells were replaced 
with fresh medium, including FBS. Next, the wells were treated 
with 10mg/mL ethanolic extract of Morinda citrifolia L. and the 
cell numbers were counted following 1-8 days. A control group was 
prepared simultaneously and a growth curve was generated.
Cell Viability Assay
The effects of Noni extract treatment on cell viability 
were determined by MTT assay, which is based on the reduction of 
a tetrazolium salt by mitochondrial dehydrogenase in viable cells. 
For all experimental groups, cells were seeded in 96-well plates at a 
density of 1 × 104 cells/well and treated with Noni extract at a final 
concentration of 1 to 80mg/mL . After 48 h, 50 μL of MTT stock 
solution (2 mg/mL) was added to each well to reach a total reaction 
volume of 250 μL, and the plates were incubated for an additional 4 h. 
Supernatants were aspirated, and the resulting formazan crystals were 
dissolved in 150 μL isopropyl alcohol. Absorbance was measured 
at 540 nm using a colorimetric MTT ELISA assay (VERSAmax 
Tunable microplate reader, Molecular Devices, CA, USA).
Antibacterial activity assay
Antibacterial activity was tested by means of a standard 
agar plate diffusion assay. Gram positive Staphylococcus aureus 
(CCBM 0324) and Gram negative Escherichia coli bacterial 
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strains (obtained from the Culture Collection of Microorganisms 
of Bahia (CCMB), Laboratory of Microbiology, University 
Estadual de Santa Cruz, Ilhéus) were used. Tests were repeated 
and was calculated at Minimum Inhibitory Concentration (MIC). 
MIC as recommended by the Institute of Clinical and Laboratory 
Standards (CLSI, 2007) and adapted9. Evaluation of antitumor 
activity was done by determining the cell growth curve in the 
presence of 10mg/mL ethanolic extracts of Morinda citrifolia L. 
Statistical Analysis
Data are presented as mean ± SD of four independent 
experiments. Statistical analysis among groups was performed by 
one-way analysis of variance (ANOVA) followed by the Student–
Newman–Keuls Multiple Range Test. GraphPad Prism v.3.0 software 
was used, p < 0.05 was considered to be statistically significant.
Results
Discussion
Malignant melanoma is a cancer with a high incidence, 
malignancy and poor prognosis. This cancer is highly metastatic 
and high mortality rate. Currently, there are no methods or 
effective drugs for treatment and thus new methods are necessarily 
expected1,2.
Malignant melanoma cells exhibit enhanced survival and 
proliferation capabilities. One of the most important reasons for 
this is antiapoptosis capacity, which is the predominant problem 
for clinical tolerance of chemotherapy drugs. Therefore, the 
identification of an effective drug has been the focus of melanoma 
treatment1,2. Search for new chemopreventive and antitumor agents 
that are more effective but less toxic has kindled great interest in 
phytochemicals. Ethanolic extract Morinda Citrifolia L. fruit is one 
such compound which was used in this study. Morinda citrifolia L 
is a herbal remedy with promising anticancer properties10. 
Our results show that the rate of proliferation of B16-F10 
cells is significantly inhibited by various concentrations of ethanolic 
extract Morinda Citrifolia L. fruit (0 - 80 mg/mL) (Figure 1). 
FIGURE 1 - Antiproliferative and cytotoxic effects of ethanolic extract 
of Morinda citrifolia L in B16-F10 cells. MTT viability test showing the 
B16-F10 cells treated for 48 h with different concentrations of extract 
(0 - 80 mg/mL) (A) and after treatment with extract concentration up to 
5 mg/mL significantly reduced the number of cells (p < 0.05). (B) –Log 
[IC50]=1.167. The MTT data shown are performed in triplicates. Results 
are means ± S.E.M from four independent experiments. (*statistically 
significant against the control for P < 0.05).
FIGURE 2 - Inhibitory activity of 10mg/mL ethanolic extract of Morinda 
citrifolia L on B16-F10 cell growth. The upper line of the graph presents 
the control group without ethanolic extract of Morinda citrifolia L 
treatment and the bottom line presents the group treated with ethanolic 
extract. At the end of each time-period, the cells were trypsinized to 
produce a single cell suspension and the cell number was counted. Data 
are presented as the mean ± standard error of the mean.
Strains Concentration
10mg/mL 1mg/mL 0.1mg/mL
Staphylococcus aureus - + -
Escherichia coli + - -
CHART 1 - Minimum Inhibitory Concentration (MIC) results; + = 
inhibitory concentration.
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Following treatment of B16-F10 cells with 10 mg/mL ethanolic 
extract of fruit Morinda citrifolia L. for 8 days, the cell proliferation 
rate was only 45% (Figure 2). Moreover, the time-dependent assay 
confirmed ethanolic extract Morinda citrifolia L. fruit exhibited a 
longlasting suppressive effect on the B16-F10 cells.
It has shown to inhibit the growth of tumor cells in 
experimental model systems, but little is known about its potential 
as an adjuvant chemotherapeutic agent11-14.
The ethanolic extract of Morinda citrifolia L. fruit 
showed bacterial growth inhibition for Staphylococcus aureus 
and Escherichia coli compared to the positive control (Chart 1) 
Minimum Inhibitory Concentration (MIC), 1mg/mL determines 
the lowest concentration that is unanswered to inhibit bacterial 
growth. Thus, we investigated the bacterial susceptibility of gram-
positive (Staphylococcus aureus) and Gram-negative (Escherichia 
coli) to the ethanolic extract. The choice of these microorganisms 
for the experiments is associated with the routine use of these 
strains for evaluation of antimicrobial activity. Moreover, these 
bacteria are human pathogens commonly isolated in Brazilian 
hospitals, representing 22.8% and 13.8% of isolates, respectively 
and often acquire resistance to antibiotics used (15)14. 
Thus, the search for new antibacterial agents is important 
for infection control. Our results show that the ethanolic extract of 
Morinda citrifolia L. has antimicrobial activity, inhibiting the growth 
of both gram-positive as gram-negative bacteria. The extract showed 
MIC ranging 1 mg /mL and 10 mg/mL, showing greater effectiveness 
against Staphylococcus aureus strains (Chart 1) where it exhibited a 
similar pattern to that caused by the antibiotic inhibition Ampicillin. 
For strain of Escherichia coli MIC was 10 mg/mL (Chart 1). These 
data corroborate others authors reported that the antimicrobial activity 
of the extract of Morinda citrifolia L, showing that its compounds 
may exhibit potent antibiotic activity against human pathogens 
such as Staphylococcus aureus, Bacillus subtilis, Escherichia coli, 
Pseudomonas aeruginosa, Salmonella and Shigella16,17. 
The inhibitory of microbial growth may be attributed to the 
presence of phenolic compounds in the plant. There is evidence that 
the Noni extract can also submit antituberculosis action, inhibiting 
the growth of Mycobacterium turbeculosis18. Moreover, conducted 
studies demonstrating satisfactory for antihelmintic activity with 
aqueous and ethanol extracts of Morinda citrifolia L. fruit. Although 
we found an inhibitory effect against pathogenic microorganisms, 
other studies should be performed to confirm and isolate the 
secondary metabolites that exhibit antimicrobial activity19.
Morinda citrifolia L fruit is widely used in alternative 
medicine for the treatment and prevention of tumors. Currently, 
there are many pre-clinical trials (animal model or in vitro). These 
studies have opened new perspectives for the understanding and 
medical use of this plant. Randomized clinical trials have to be 
performed to conclusive determination of their effects on human 
disease. Especially considering the antitumoral activity, this fruit 
can have a major role in the anticancer therapy10.
Conclusions
The ethanolic extract Morinda citrifolia L. fruit induce 
cell growth inhibition on Staphylococcus aureus and Escherichia 
coli and cell growth inhibition on B16-F10 cells. Considering the 
acquire resistance to antibiotics used and chemoresistance exhibited 
by melanoma towards conventional chemotherapy drugs, this novel 
compound may provide promising improvements in the therapeutic 
approach to infectious diseases and melanoma treatment.
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